AB Foundation for Medical Research Report issue

Foundation Phase 2 Phase 3
Founded: Edmonton Canada (1980)

Organization Overview

First Clinical Trial
2004
NCT00373776
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ABF Foundation for Medical Research | AB Foundation | Jonathan Berman

Active Ingredients

Drugs in Phase 3 Trials (3)

amphotericin b (fungizone) (1 trial)

antimony (4 trials)

miltefosine (impavido) (9 trials)

Drugs in Phase 2 Trials (1)

pentamidine (pentam) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 2)

Leishmaniasis, Cutaneous (Phase 2)

Leishmaniasis, Visceral (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 4